Ipilimumab
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Ipilimumab and local guidelines before prescribing.
Mechanism
CTLA-4 inhibitor augmenting T-cell activation.
Uses
Melanoma, renal cell carcinoma (combination), other cancers.
Dosing
No dose is given in the chapters. See the BNF.
Side effects
Immune-related colitis, hepatitis, dermatitis, endocrinopathies (hypophysitis), pneumonitis.
Interactions
Corticosteroids reduce effect.
Contraindications and cautions
Autoimmune disease caution
Monitoring
LFT, TFT, cortisol, U&E
Pregnancy and breastfeeding
Avoid
Renal and hepatic impairment
No adjustment
Overdose and reversal
Supportive; steroids
Special advice
Severe diarrhoea needs urgent assessment; steroids early; endocrinopathy cover.
More from the textbook: uses, cautions and other points
- An immune-related adverse event of PD-1, PD-L1 and CTLA-4 inhibitors (e.g. pembrolizumab, nivolumab, ipilimumab). Uncommon (about 1%) but with mortality of up to a quarter to a half in fulminant cases.
Cardiology: Cardiomyopathies - A 62-year-old man on nivolumab and ipilimumab develops ptosis, proximal weakness and a troponin of 900 ng/L four weeks after starting. Answer: Checkpoint-inhibitor myocarditis with myositis/myasthenia overlap - stop immunotherapy, IV methylprednisolone, ECG monitoring for heart block, involve oncology, neurology and cardiology.
Cardiology: Cardiomyopathies - Mechanism: Checkpoint inhibitors (pembrolizumab, nivolumab, atezolizumab, durvalumab, ipilimumab) release the brakes on the immune system. As well as attacking the cancer, they can cause immune-related adverse events in almost any organ - at any time, even months after stopping.
Respiratory: Lung Cancer - Nivolumab + ipilimumab | First-line immunotherapy for mesothelioma (NICE TA818).
Respiratory: Lung Cancer - Immunotherapy (nivolumab plus ipilimumab, NICE TA818) or chemotherapy (platinum plus pemetrexed).
Respiratory: Lung Cancer - NICE TA818: Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma
Respiratory: Lung Cancer - Immune checkpoint inhibitors (pembrolizumab, nivolumab, ipilimumab) | Thyroiditis, hypophysitis (ACTH deficiency - headache, fatigue), adrenalitis, sudden type 1 diabetes and DKA
Endocrine: Anatomy Physiology and Pharmacology - Immune checkpoint inhibitor hypophysitis: Especially with ipilimumab (anti-CTLA-4), usually within the first 2–3 months of treatment. Causes headache and fatigue, with ACTH, TSH and gonadotrophin deficiency. The ACTH deficiency is usually permanent .
Endocrinology: Pituitary Disease
Where it is discussed in the book
- Cardiology: Cardiomyopathies (2 mentions)
- Respiratory: Lung Cancer (4 mentions)
- Endocrine: Anatomy Physiology and Pharmacology (1 mention)
- Endocrinology: Pituitary Disease (2 mentions)
- Endocrinology: Adrenal Disease (2 mentions)
- Gastroenterology: Inflammatory Bowel Disease (2 mentions)
- Oncology: Principles (3 mentions)
- Oncology: Emergencies (1 mention)
- Oncology: Urology and Genital cancers (2 mentions)
- Oncology: Skin Cancer (1 mention)
- Dermatology: Skin lesions and skin cancer (2 mentions)
- Rheumatology: Emergencies, pregnancy and other systemic diseases (2 mentions)
- Clinical Immunology: Biologics, immunotherapy, checkpoint toxicity and transplant immunology (6 mentions)
- Integrated cardiology chapter (2 mentions)
- Integrated respiratory chapter (4 mentions)
- Cell Biology: Cell cycle, signalling, cell death and stem cells (1 mention)